We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+12.31%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.4B
AUM Growth
-$103M
(-6.9%)
Cap. Flow
-$192M
Cap. Flow
% of AUM
-13.74%
Top 10 Holdings %
Top 10 Hldgs %
58.28%
Holding
52
New
10
Increased
7
Reduced
7
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYBX
CYBERONICS INC
CYBX
|
+$45.7M |
| 2 |
AbbVie
ABBV
|
+$45.3M |
| 3 |
SEM
Select Medical
SEM
|
+$41.6M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$34.9M |
| 5 |
MDCO
Medicines Co
MDCO
|
+$33.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$74.8M |
| 2 |
VOLC
VOLCANO CORPORATION COM STK
VOLC
|
+$45.6M |
| 3 |
Viatris
VTRS
|
+$42.3M |
| 4 |
CONMED
CNMD
|
+$35M |
| 5 |
Boston Scientific
BSX
|
+$33.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.03% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $206M | 14.74% |
1,000,000
| – | – |
|
2
Teva Pharmaceuticals
TEVA
$40.4B
| $103M | 7.34% |
1,650,000
-100,000
| -6% | -$5.81M |
|
|
MASI
3
DELISTED
Masimo
MASI
| $89M | 6.36% |
2,700,000
-150,000
| -5% | -$4.31M |
|
|
MDCO
4
DELISTED
Medicines Co
MDCO
| $70M | 5% |
2,500,000
+1,180,000
| +89% | +$33.1M |
|
|
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
| $64.2M | 4.58% |
2,100,000
-50,000
| -2% | -$1.59M |
|
|
ESRX
6
DELISTED
Express Scripts Holding Company
ESRX
| $60.7M | 4.34% |
700,000
| – | – |
|
|
ARIA
7
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $57.7M | 4.12% |
7,000,000
-500,000
| -7% | -$3.7M |
|
|
UAM
8
DELISTED
Universal American Corp
UAM
| $55.9M | 3.99% |
5,234,898
+666,000
| +15% | +$6.26M |
|
|
AMAG
9
DELISTED
AMAG Pharmaceuticals
AMAG
| $55.7M | 3.97% |
1,018,246
+18,246
| +2% | +$870K |
|
10
Orthofix Medical
OFIX
$492M
| $53.8M | 3.84% |
1,500,000
+250,000
| +20% | +$7.86M |
|
11
Labcorp
LH
$25.2B
| $50.4M | 3.6% |
465,600
-116,400
| -20% | -$12M |
|
|
CYBX
12
DELISTED
CYBERONICS INC
CYBX
| $48.7M | 3.48% |
+750,000
| New | +$45.7M |
|
|
SEM
13
DELISTED
Select Medical
SEM
| $44.5M | 3.18% |
+5,568,000
| New | +$41.6M |
|
|
14
AbbVie
ABBV
$465B
| $43.9M | 3.13% |
+750,000
| New | +$45.3M |
|
|
KERX
15
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $38.2M | 2.73% |
3,000,000
| – | – |
|
16
Bruker
BRKR
$9.4B
| $36.9M | 2.64% |
2,000,000
| – | – |
|
|
KND
17
DELISTED
Kindred Healthcare
KND
| $35.7M | 2.55% |
1,500,000
| – | – |
|
|
SQNM
18
DELISTED
SEQUENOM INC NEW
SQNM
| $35.5M | 2.54% |
9,000,000
+250,000
| +3% | +$918K |
|
|
19
CONMED
CNMD
$1.3B
| $33.9M | 2.42% |
670,943
-714,057
| -52% | -$35M |
|
|
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $32.8M | 2.34% |
+750,000
| New | +$34.9M |
|
|
AMRN
21
Amarin Corp
AMRN
$297M
| $28.1M | 2% |
600,000
| – | – |
|
|
GNMK
22
DELISTED
GenMark Diagnostics, Inc
GNMK
| $19.2M | 1.37% |
1,482,662
-265,438
| -15% | -$3.47M |
|
|
TRVN
23
DELISTED
Trevena, Inc.
TRVN
| $18.7M | 1.34% |
4,592
| – | – |
|
|
CCRN
24
DELISTED
Cross Country Healthcare
CCRN
| $16.9M | 1.2% |
1,422,565
| – | – |
|
|
EPRS
25
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $16.5M | 1.18% |
+1,847,500
| New | +$14.8M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Camber Capital Management held 52 positions worth $1.4B, down 6.9% from $1.5B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Camber Capital Management withdrew a net $192M in Q1 2015, closing 17 positions and reducing 7 holdings. Its most notable exit was GSK, an estimated $74.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 59% a quarter earlier, followed by Consumer Discretionary.
Against the trend, Camber Capital Management opened a new position in CYBERONICS INC worth $48.7M.
- Camber Capital Management's largest Q1 2015 buy was CYBERONICS INC: 750,000 shares worth $48.7M.
- Camber Capital Management added most to Medicines Co in Q1 2015, an estimated $33.1M increase.
- Camber Capital Management's biggest Q1 2015 reduction was CONMED, cutting an estimated $35M.
- Camber Capital Management fully exited GSK in Q1 2015, selling an estimated $74.8M.
- Camber Capital Management's ten largest holdings make up 58% of its $1.4B portfolio in Q1 2015.
- Camber Capital Management opened 10 new positions and closed 17 in Q1 2015.
- Camber Capital Management's portfolio value fell 6.9% quarter-over-quarter to $1.4B.
Based on Camber Capital Management's 13F filing for Q1 2015, filed 15 May 2015.